EVO Visian ICL
-
Broadwood Partners Comments on STAAR Surgical Shareholder Vote Against Alcon Acquisition
STAAR Surgical shareholders have rejected Alcon’s acquisition bid, empowering the company to pursue independent growth. This decision, heavily influenced by major shareholder Broadwood Partners, allows STAAR to capitalize on its innovative EVO Visian ICL technology and strong market position in refractive error correction. The company faces opportunities and challenges in scaling production and expanding market reach, with a focus on its proprietary Collamer material and future R&D. Broadwood Partners expressed confidence in STAAR’s standalone prospects and commitment to unlocking its full potential.
